Register for our free email digests:
Intercept Pharmaceuticals Inc.
www.interceptpharma.com
Latest From Intercept Pharmaceuticals Inc.
Genfit Addresses Multiple Transition Issues With CEO Change
Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.
ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
Conatus Accepts Defeat For Emricasan In NASH
After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.
Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity
As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Intercept Pharmaceuticals Inc.
- Senior Management
-
Mark Pruzanski , MD, Pres. & CEO
Sandip Kapadia, CFO
David Shapiro, MD, CMO
Jerome Durso, COO - Contact Info
-
Intercept Pharmaceuticals Inc.
Phone: (646) 747-1000
10 Hudson Yards
37th Fl.
New York, NY 10001
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice